Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Additionally, established products like Repatha and Tezspire continue to demonstrate strong market presence. The company’s pipeline remains a key focus for investors and analysts alike. Amgen has ...

Additionally, established products like Repatha and Tezspire continue to demonstrate strong market presence. The company's pipeline remains a key focus for investors and analysts alike.

Amgen only had four or five marketed products when Thompson joined the company in 2008. Now, the company has four product portfolio areas: general medicine, rare diseases, inflammation, and oncology.